ArticleEndocrine2026
Comparable epicardial adipose tissue burden in prediabetes with high cardiometabolic risk and early type 2 diabetes: A need for timely targeted therapies.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpicardial adipose tissue (EAT) independently predicts adverse cardiovascular events. Prediabetes with metabolic syndrome carries high cardiovascular risk, yet EAT in this critical subpopulation versus incident type-2 diabetes (T2D) remains unexplored.
methodsCoronary CT-angiography records were retrospectively reviewed to compare adults with prediabetes (impaired fasting glucose 110–125 mg/dL and HbA1c < 6.5%) having ≥ 3 of 4 cardiometabolic risk indicators (overweight/obese, hypertension, statin use/hypertriglyceridemia, and statin use/low HDL-cholesterol; n = 44) with drug-naïve T2D (n = 44) and normoglycemic individuals (n = 50). Groups were matched for age, gender, body mass index (BMI), hypertension, statin use, smoking and coronary artery calcium score (CACS). EAT volume and attenuation were quantified using semi-automated software.
resultsThe high-risk prediabetes cohort (median age 53.5 [IQR 47–61] years; males 59.1%; overweight/obese, 95.5%; CACS > 0, 47.7%) exhibited EAT volume similar to T2D (median [IQR]: 93 [76.5-120.5] mL versus 88.4 [72.5–112] mL; pbonferroni=0.713), with both being significantly greater than normoglycemic individuals (72.8 [51–104] mL, pbonferroni<0.05). EAT/height2, EAT/body surface area(BSA) and EAT/BMI demonstrated similar trends; whereas average EAT attenuation did not differ across the groups. EAT/BSA demonstrated highest discriminatory ability for prediabetes (AUC = 0.683) and T2D (AUC = 0.692) from normoglycemia (p < 0.007). An EAT/BSA threshold of 48.0 mL/m2 for high-risk prediabetes yielded 66% specificity and 70.5% sensitivity.
conclusionSubstantial EAT accumulation is evident in individuals with prediabetes and additional cardiometabolic risk indicators such as overweight, hypertension, and dyslipidemia. These findings highlight a critical need to explore timely targeted interventions to mitigate cardiovascular risk in this vulnerable subgroup akin to those employed in T2D.
Indexed as
Identifiers
41491446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.